Literature DB >> 3810695

5 Alpha-reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat.

J R Brooks, C Berman, R L Primka, G F Reynolds, G H Rasmusson.   

Abstract

Inhibition of 5 alpha-reductase and anti-androgenicity were studied in rats treated with various 4-azasteroids. The known inhibitor, N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxamide (4-MA) served as a reference compound, and analogs of this basic molecule were assayed. Enhancement of enzyme inhibitory potency was usually seen with delta 1 analogs, whereas reduction in activity was noted with substitutuents such as delta 5, a spirotetrahydrofuran ring at C-17 or 4-deaza groups. Many of the 4-azasteroids had a much greater oral anti-androgenic effect against testosterone propionate (TP) than dihydrotestosterone propionate (DHTP). This difference in activity versus the two androgens is believed to reflect the necessity for TP to undergo reduction to DHT before becoming capable of stimulating prostatic growth. Inhibition of 5 alpha-reductase by active compounds prevented the conversion, thereby producing an anti-androgenic effect. In this regard, certain delta 1 analogs of 4-MA, particularly those bearing a 17 beta-(N-tert butylcarbamoyl) group, proved very effective against TP but were relatively inactive versus DHTP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3810695     DOI: 10.1016/0039-128x(86)90072-3

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  7 in total

Review 1.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

Review 2.  Benign prostatic hyperplasia. Practical treatment guidelines.

Authors:  T Tammela
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

3.  Solid-phase synthesis of model libraries of 3alpha,17beta-dihydroxy-16alpha-(aminoethyl-N-substituted)-5alpha-androstanes for the development of steroidal therapeutic agents.

Authors:  René Maltais; Caroline Mercier; Fernand Labrie; Donald Poirier
Journal:  Mol Divers       Date:  2005       Impact factor: 2.943

Review 4.  Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

5.  Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase.

Authors:  F W George; D W Russell; J D Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

6.  Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers.

Authors:  M Ohtawa; H Morikawa; J Shimazaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

7.  Optimization and validation of spectrophotometric methods for determination of finasteride in dosage and biological forms.

Authors:  Alaa S Amin; Mohammed A Kassem
Journal:  Pharm Methods       Date:  2012-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.